MCID: HMG002
MIFTS: 48

Hemoglobinuria

Categories: Immune diseases, Blood diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to hepatitis and malaria, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Cyclophosphamide and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotype is hematopoietic system.

Wikipedia : 72 In medicine, hemoglobinuria or haemoglobinuria is a condition in which the oxygen transport protein... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.1 CD59 HP PIGA
2 malaria 28.1 CD55 CR1 HP PLAUR
3 paroxysmal nocturnal hemoglobinuria 12.4
4 paroxysmal cold hemoglobinuria 12.3
5 paroxysmal nocturnal hemoglobinuria, somatic 12.2
6 paroxysmal nocturnal hemoglobinuria 2 12.1
7 aplastic anemia 11.2
8 blackwater fever 11.1
9 warm antibody hemolytic anemia 10.8
10 multiple mitochondrial dysfunctions syndrome 10.6 PIGA PIGT
11 orbital periostitis 10.5 C5 CD55
12 mental retardation, x-linked, snyder-robinson type 10.4 CD55 CD59 PIGA
13 der kaloustian mcintosh silver syndrome 10.4 C3 C5
14 acquired hemophilia 10.4 C3 HP
15 periventricular heterotopia with microcephaly 10.3 CD55 CD59 PIGT
16 gastric cardia carcinoma 10.3 C3 C5
17 ovarian endometrioid cystadenoma 10.3 CD55 CD59 HP
18 thrombosis 10.3
19 autonomic peripheral neuropathy 10.2 C3 HP
20 budd-chiari syndrome 10.1
21 hemolytic uremic syndrome, atypical 3 10.1 C3 CR1
22 leukemia 10.1
23 malignant hypertension 10.1 HP MB
24 myelodysplastic syndrome 10.0
25 hemoglobinemia 10.0
26 cerebritis 10.0
27 thrombocytopenia 10.0
28 diffuse glomerulonephritis 9.9 C3 CR1
29 van maldergem syndrome 2 9.9 C3 CR1
30 hemolytic anemia 9.9
31 hematopoietic stem cell transplantation 9.9
32 purpura 9.9
33 lymphoma 9.8
34 retinitis 9.8
35 heparin-induced thrombocytopenia 9.8
36 hypocalciuric hypercalcemia, type i 9.8 CD55 CD59 PIGA
37 neutropenia 9.8
38 hemosiderosis 9.8
39 multiple myeloma 9.7
40 pancytopenia 9.7
41 autoimmune hemolytic anemia 9.7
42 fasciitis 9.7
43 inherited bone marrow failure syndromes 9.7
44 myocardial infarction 9.6
45 systemic lupus erythematosus 9.6
46 hepatocellular carcinoma 9.6
47 hodgkin lymphoma 9.6
48 eosinophilic fasciitis 9.6
49 acute leukemia 9.6
50 chronic lymphocytic leukemia 9.6

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria, other and unspecified genitourinary symptoms

MGI Mouse Phenotypes related to Hemoglobinuria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 FCGR3B HP MB PIGA PLAUR C3

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 50-18-0, 6055-19-2 2907
2
Fludarabine Approved Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
3
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
4 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
5
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
6
Iodine Investigational Phase 3 7553-56-2 807
7 Cyclosporins Phase 3,Phase 2,Phase 1
8 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antilymphocyte Serum Phase 3,Phase 2
10 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
11 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antibodies Phase 3,Phase 2
13 Immunoglobulins Phase 3,Phase 2
14 Muromonab-CD3 Phase 3,Phase 2
15 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
17 Complement System Proteins Phase 3,Phase 2,Phase 1
18 Complement Inactivating Agents Phase 3,Phase 1,Phase 2
19
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
20
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
21
alemtuzumab Approved, Investigational Phase 2,Phase 1,Early Phase 1 216503-57-0
22
Melphalan Approved Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
23
Lenograstim Approved Phase 2 135968-09-1
24
Basiliximab Approved, Investigational Phase 2 152923-56-3, 179045-86-4
25
Busulfan Approved, Investigational Phase 2,Early Phase 1 55-98-1 2478
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
28
Vidarabine Approved Phase 1, Phase 2, Early Phase 1 24356-66-9 32326 21704
29
Mechlorethamine Approved Phase 2 51-75-2 4033
30
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
32
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
33
Mesna Approved Phase 2 3375-50-6 598
34
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
35
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
36
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
37
Everolimus Approved Phase 2 159351-69-6 6442177
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
39
Nandrolone Approved, Experimental, Illicit Phase 1, Phase 2 434-22-0, 62-90-8 9904 229455
40
Nandrolone decanoate Approved, Illicit Phase 1, Phase 2 360-70-3 9677
41
Etoposide Approved Phase 2 33419-42-0 36462
42 tannic acid Approved, Nutraceutical Phase 2
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
44
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
45
Treosulfan Investigational Phase 2 299-75-2 9296
46 Adjuvants, Immunologic Phase 2,Phase 1
47 Anthelmintics Phase 2
48 Antifungal Agents Phase 2,Phase 1
49 Anti-Infective Agents Phase 2,Phase 1,Early Phase 1
50 Antiparasitic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 98)

id Name Status NCT ID Phase Drugs
1 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Completed NCT00867932 Phase 4 Eculizumab
2 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00098280 Phase 3 Eculizumab
3 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00130000 Phase 3 Eculizumab
4 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00122317 Phase 3 eculizumab
5 Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT00112983 Phase 3
6 Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT00122330 Phase 3 eculizumab
7 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed NCT00122304 Phase 3 eculizumab
8 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
9 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
10 Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
11 ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
12 ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
13 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Enrolling by invitation NCT02393508 Phase 3
14 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
15 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
16 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
17 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
18 Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure Unknown status NCT00895739 Phase 2 cyclosporine
19 E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01194804 Phase 2 Eculizumab
20 C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01192399 Phase 2
21 A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
22 Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
23 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
24 Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome Completed NCT00731328 Phase 2
25 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
26 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
27 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
28 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
29 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
30 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
31 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
32 Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases Completed NCT02277639 Phase 2
33 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
34 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Recruiting NCT02591862 Phase 2 Coversin
35 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03053102 Phase 2 ACH-0144471
36 Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT03157635 Phase 1, Phase 2 RO7112689;Placebo
37 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT02534909 Phase 2
38 Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study Recruiting NCT03225287 Phase 2 RA101495
39 Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab Recruiting NCT03030183 Phase 2 RA101495
40 Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Recruiting NCT03078582 Phase 2 RA101495
41 A Long-term Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03181633 Phase 2 ACH-0144471
42 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
43 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Recruiting NCT00003838 Phase 2
44 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Recruiting NCT02224872 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolic acid mofetil
45 Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases Recruiting NCT02349906 Phase 2 Treosulfan;Busilvex
46 Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2 RIC regimen;GVHD prophylaxis regimen
47 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
48 Nandrolone Decanoate in the Treatment of Telomeropathies Recruiting NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
49 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
50 Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Recruiting NCT01597219 Phase 2

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

id Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

39
Bone, Bone Marrow, T Cells, Kidney, Testes, Myeloid, Neutrophil

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 839)
id Title Authors Year
1
Multiple Lacunar Infarcts in Paroxysmal Nocturnal Hemoglobinuria. ( 28781057 )
2017
2
Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. ( 28437723 )
2017
3
Paroxysmal Nocturnal Hemoglobinuria in the Differential Diagnosis of Thrombocytopenia. ( 28435653 )
2017
4
Paroxysmal Nocturnal Hemoglobinuria in a Case of Chronic Anemia. ( 28527178 )
2017
5
Standardized high-sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria in children with acquired bone marrow failure disorders: A single center US study. ( 28574201 )
2017
6
Severe Neutropenia After Leukocytosis During an Acute Attack of Mycoplasma Infection-associated Paroxysmal Cold Hemoglobinuria. ( 28234745 )
2017
7
Primary Myoglobinuria: Differentiate Myoglobinuria from Hemoglobinuria. ( 28811700 )
2017
8
Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients. ( 27807852 )
2017
9
The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea. ( 28698856 )
2017
10
Immune Hemolytic Anemia (Paroxysmal Cold Hemoglobinuria) Preceding Burkitt Lymphoma in a 12-Year-Old Child. ( 27879544 )
2017
11
Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. ( 28646725 )
2017
12
Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes. ( 28452421 )
2017
13
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. ( 28332730 )
2017
14
Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation. ( 28811010 )
2017
15
Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. ( 28124384 )
2017
16
Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. ( 28447244 )
2017
17
Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. ( 28528998 )
2017
18
Fluorescent Aerolysin (FLAER)-based paroxysmal nocturnal hemoglobinuria (PNH) screening: a single center experience from India. ( 28432724 )
2017
19
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. ( 27837250 )
2017
20
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. ( 28124080 )
2017
21
A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients. ( 28380398 )
2017
22
Acute kidney injury in a postpartum woman with paroxysmal nocturnal hemoglobinuria: A case report and literature review. ( 28796431 )
2017
23
Renal Biopsy in Paroxysmal Nocturnal Hemoglobinuria: An Insight into the Spectrum of Morphologic Changes. ( 28761230 )
2017
24
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. ( 28246555 )
2017
25
Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants. ( 28692147 )
2017
26
Role of kidney MRI to monitoring clearance of hemosiderin deposits in paroxysmal nocturnal hemoglobinuria. ( 28434706 )
2017
27
Kids, colds, and complement: paroxysmal cold hemoglobinuria. ( 28594143 )
2017
28
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry. ( 28748287 )
2017
29
Pathology of Naturally Occurring Bacillary Hemoglobinuria in Cattle. ( 28438111 )
2017
30
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report. ( 28328837 )
2017
31
Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123(13):2094-2101. ( 28408428 )
2017
32
Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia. ( 28675769 )
2017
33
T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways. ( 28630090 )
2017
34
Cerebral Stroke in a Teenage Girl with Paroxysmal Nocturnal Hemoglobinuria. ( 28626543 )
2017
35
Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria. ( 28761231 )
2017
36
Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. ( 27884975 )
2016
37
Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. ( 26852134 )
2016
38
Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm. ( 27313483 )
2016
39
Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis. ( 27757214 )
2016
40
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. ( 27536121 )
2016
41
Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. ( 27810992 )
2016
42
Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go? ( 26990688 )
2016
43
Performance characteristics of a non-fluorescent aerolysin-based paroxysmal nocturnal hemoglobinuria (PNH) assay for simultaneous evaluation of PNH neutrophils and PNH monocytes by flow cytometry, following published PNH guidelines. ( 27294344 )
2016
44
Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: a retrospective single-center study. ( 27761934 )
2016
45
Pathogenesis of paroxysmal nocturnal hemoglobinuria. ( 27725586 )
2016
46
Technical advances in flow cytometry-based diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria. ( 27759825 )
2016
47
Successful Treatment of Ascites using a Denver(Ar) Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome. ( 27746432 )
2016
48
Zonal cutaneous ulceration and necrosis of the lower abdomen due to cutaneous thrombosis associated with paroxysmal nocturnal hemoglobinuria. ( 27790741 )
2016
49
Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome: a case report. ( 26744238 )
2016
50
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. ( 26839475 )
2016

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 C3 C5 CD14 CD55 CD58 CD59
2
Show member pathways
11.98 C3 CR1 FCGR3B
3 11.96 C3 CD14 CR1 FCGR3B
4 11.88 C3 CD14 FCGR3B
5
Show member pathways
11.82 C3 C5 CD55 CD59 CR1
6
Show member pathways
11.68 C3 C5 CD55 CD59 CR1
7
Show member pathways
11.66 FCGR3B PIGA PIGT PLAUR
8 11.62 C3 CR1 FCGR3B
9 11.61 CD14 CD55 CD59 CR1
10 11.55 C3 C5 CD14
11 11.38 C3 C5 FCGR3B
12
Show member pathways
11.38 C3 C5 CD55 CD59 CR1
13 11.35 C3 CD14 CR1
14 11.24 C3 C5 CD55 CD59 CR1 PLAUR
15
Show member pathways
11.16 PIGA PIGT

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 C3 C5 CD14 CD55 CD59 FCGR3B
2 extracellular exosome GO:0070062 9.9 C3 C5 CD14 CD55 CD58 CD59
3 extracellular space GO:0005615 9.83 C3 C5 CD14 CD59 HP
4 cell surface GO:0009986 9.73 CD14 CD55 CD58 CD59 CR1 PLAUR
5 ficolin-1-rich granule membrane GO:0101003 9.5 CD55 CD58 CR1
6 anchored component of external side of plasma membrane GO:0031362 9.4 CD14 CD59
7 secretory granule membrane GO:0030667 9.35 CD14 CD55 CD58 CR1 FCGR3B
8 anchored component of membrane GO:0031225 9.17 CD14 CD55 CD58 CD59 FCGR3B PLAUR

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.77 C3 C5 CD14 CD55 CR1
2 inflammatory response GO:0006954 9.76 C3 C5 CD14 SEMA7A
3 positive regulation of protein phosphorylation GO:0001934 9.65 C3 PLAUR SEMA7A
4 immune system process GO:0002376 9.65 C3 C5 CD14 CD55 CR1
5 GPI anchor biosynthetic process GO:0006506 9.51 PIGA PIGT
6 positive regulation of vascular endothelial growth factor production GO:0010575 9.49 C3 C5
7 complement activation, classical pathway GO:0006958 9.46 C3 C5 CD55 CR1
8 positive regulation of interleukin-8 secretion GO:2000484 9.43 CD14 CD58
9 complement activation, alternative pathway GO:0006957 9.4 C3 C5
10 regulation of complement activation GO:0030449 9.35 C3 C5 CD55 CD59 CR1
11 attachment of GPI anchor to protein GO:0016255 9.32 PIGT PLAUR
12 neutrophil degranulation GO:0043312 9.28 C3 CD14 CD55 CD58 CD59 CR1

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 8.96 C3 C5
2 receptor binding GO:0005102 8.92 C3 C5 CD58 PLAUR

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....